CEO, Managing Director
Mr. Richards has more than 27 years’ international experience in the pharmaceutical industry and has worked in Europe, the US and Asia. Prior to joining Mayne Pharma, Mr Richards spent 10 years in Europe in a variety of leadership roles including President, Europe Middle East and Africa and President, Global Commercial Operations for Mayne Pharma Limited (acquired by Hospira in 2007). Mr. Richards also served on the Group Management Board of Actavis for 4 years where he was responsible for the firm’s global injectable/hospital business operations. Prior to working in Europe, Mr. Richards spent 14 years with FH Faulding and Co (acquired by Mayne Nickless in 2001) in a variety of roles including leading Faulding Pharmaceuticals Asia Pacific operations together with spending 5 years with Faulding in the United States leading business development and portfolio management operations.
Chief Financial Officer & Company Secretary
Mr. Cansdale is a Chartered Accountant and company secretary with more than 20 years’ experience in the accounting and finance profession. Mr. Cansdale was formerly the CFO and Company Secretary at McMillan Shakespeare Limited and prior to that, Vision Systems Limited. Mr. Cansdale has extensive experience in the areas of business development, mergers and acquisitions, corporate strategy, tax, financial planning and analysis, risk management, treasury and investor relations. Prior to joining Vision Systems in 2002, Mark held senior finance positions in the insurance and financial services industry at Norwich Union Australia and KPMG.
Chief Commercial Officer
Prior to joining Mayne Pharma, Mr. Cross was Head of Marketing (Asia Pacific) for Hospira Inc., a leading global provider of pharmaceuticals and medical devices, where he was responsible for expansion of the new product portfolio and on-market product growth across all markets in the region. He has more than 20 years’ experience in the pharmaceutical industry having also worked at Mayne Pharma Limited (previously FH Faulding & Co) across strategy, business development/M&A, sales and marketing, HR and finance/IT.
Chief Scientific Officer
Dr. Stancovski has over 20 years of international experience in the pharmaceutical industry and academia. She has been instrumental in driving Mayne’s pipeline selection, the global development of branded and generic products and the regulatory approval of NDAs, ANDAs and 505(b)2 dossiers. Prior to joining Mayne Pharma, Dr. Stancovski was Vice President of Research & Development for Actavis Group’s global Hospital Division where she made a significant contribution to advancing the company’s injectable pipeline. Prior to Actavis, Dr. Stancovski was the Vice President Scientific Affairs at Intas Pharmaceuticals Limited and also held senior management roles at other multinational pharmaceutical and biotech companies. She holds a Ph.D. in Life Sciences from the Weizmann Institute, Israel and worked as a post-doctoral scholar at Caltech and MIT in the United States.
Executive Vice President and General Counsel
Ms. Rintoul has over 15 years of varied experience in commercial and IP law. Prior to joining Mayne Pharma, Ms. Rintoul was special counsel at Minter Ellison Lawyers where she worked closely with Mayne Pharma on various agreements and transactions. Ms. Rintoul has also worked for Shell International in The Hague as IP Counsel and for the University of British Columbia’s technology transfer office in Vancouver as a consultant. She has a BSc in Biochemistry, a LLB (Hons) degree and Master of Law (Intellectual Property) from the University of Melbourne.
Chief Development Officer, Head of M&A
Mr. Paltoglou has over 15 years of experience in executing public and private mergers and acquisitions, capital management and providing strategic advice across a range of contexts and market sectors. He was previously Managing Director of Investment Banking at Credit Suisse Emerging Companies in Australia. Prior to Credit Suisse, Mr. Paltoglou was a Director of Hindal Group, a boutique M&A advisory business.
Vice President, Investor Relations and Communications
Ms. Pendlebury has more than 17 years of experience in the finance industry and has worked with companies including JP Morgan, CVC Asia Pacific and Pacific Brands. Ms. Pendlebury commenced working for Mayne Pharma in 2010 overseeing the investor relations function and was actively involved in all the transformational acquisitions. Ms. Pendlebury has extensive experience in the areas of business development, mergers and acquisitions, corporate strategy, investor relations and corporate governance.